WHO ICTRP trial
A research study to find out whether tipifarnib is safe and effective for the…
EUCTR2016-001396-69-ES · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2016-001396-69-ES |
|---|---|
| Public title | A research study to find out whether tipifarnib is safe and effective for the treatment of a lymphoma in the cases of previous treatment have failed. |
| Scientific title | An Open Label Phase II Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell LymphomaLymphoma |
| Primary sponsor | Kura Oncology Inc., |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | United States;Spain |
| Conditions | Subjects with Relapses and Refractory Peripheral T-Cell Lymphoma;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Product Name: Tipifarnib Product Code: R115777 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: tipifarnib CAS Number: 192185-72-1 Current Sponsor code: R115777 Other descriptive name: TIPIFARNIB Concentration unit: mg… |
| Registration date | May 8, 2016 |
| Target size | 30 |
| Secondary IDs | KO-TIP-002 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: